Migraine is a debilitating neurological disease that affects 1 in 10 children, often disrupting their daily lives, school performance, and overall well-being. Despite its significant impact, treatment options for pediatric migraine are limited, with very few FDA-approved therapies available for children.
Theranica is committed to transforming migraine care with the Nerivio® REN Wearable, an innovative, drug-free, and non-invasive wearable therapy designed for children and adolescents. The Nerivio is FDA-cleared for acute and/or preventive treatment of migraine with or without aura in patients 8 years of age or older. It is a prescription only, self-administered treatment for use in the home environment at the onset of migraine headache or aura for acute treatment, or every other day for preventive treatment. The Nerivio REN Wearable is the first-ever drug-free migraine treatment covered by multiple Medicaid and Commerical Insurance plans.